Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

Citi initiated coverage of Moderna (MRNA) with a Neutral rating and $40 price target Healthcare policy remains a key biopharma sector ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Researchers racing to develop bird flu vaccines for humans have turned to a cutting-edge technology that enabled the rapid development of lifesaving covid shots.

Just a couple months ago, between October 2024 and December 2024, an estimated 72,000 to 120,000 people were hospitalized due to COVID-19, underscoring the crit ...

Moderna Inc., a biotechnology and pharmaceutical company reorienting its business for a post-pandemic age, awarded almost $17 ...

Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...